DARE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
DARE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Dare Bioscience's Enterprise Value is $17.93 Mil. Dare Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-8.02 Mil. Therefore, Dare Bioscience's EV-to-FCF for today is -2.23.
The historical rank and industry rank for Dare Bioscience's EV-to-FCF or its related term are showing as below:
During the past 12 years, the highest EV-to-FCF of Dare Bioscience was 1.72. The lowest was -8.35. And the median was 1.43.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2024-12-14), Dare Bioscience's stock price is $3.18. Dare Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.621. Therefore, Dare Bioscience's PE Ratio (TTM) for today is At Loss.
The historical data trend for Dare Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-FCF | Get a 7-Day Free Trial | -0.91 | -2.05 | -4.05 | -2.00 | -0.55 |
Dare Bioscience Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial | -0.87 | -0.55 | -1.60 | -1.89 | -2.23 |
For the Biotechnology subindustry, Dare Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Dare Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Dare Bioscience's EV-to-FCF falls into.
Dare Bioscience's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 17.925 | / | -8.021 | |
= | -2.23 |
Dare Bioscience's current Enterprise Value is $17.93 Mil.
Dare Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience (NAS:DARE) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Dare Bioscience's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 3.18 | / | -0.621 | |
= | At Loss |
Dare Bioscience's share price for today is $3.18.
Dare Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.621.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Dare Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Sophia Nnenna Ononye-onyia | director | 1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020 |
Sabrina Martucci Johnson | director, officer: Chef Executive Officer | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
John A Fair | officer: Chief Strategy Officer | C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Cheryl R Blanchard | director | C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580 |
Roger Hawley | director | 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122 |
Gregory W Matz | director | 1 WHITE OAK WAY, NOVATO CA 94949 |
Jessica D. Grossman | director | C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Lisa Walters-hoffert | officer: Chief Financial Officer | C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121 |
Robin Joan Steele | director | 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Scott Eliasof | officer: SVP, Chief Scientific Officer | C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451 |
David R Walt | director | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Adrian Senderowicz | officer: SVP, Chief Medical Officer | C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
Stuart A Arbuckle | director | VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139 |
Alejandra Carvajal | officer: VP, General Counsel | C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139 |
James E Oneill | officer: Principal Accounting Officer | 15 GREENBRIAR CIRCLE, ANDOVER MA 01810 |
From GuruFocus
By Marketwired • 06-24-2024
By Marketwired • 08-13-2024
By GuruFocus Research • 03-29-2024
By Marketwired • 11-07-2024
By GuruFocus Research • 08-13-2024
By GuruFocus Research • 02-06-2024
By Marketwired • 07-19-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.